Vireo Growth Reports 170% Revenue Surge, Positive Operating Cash Flow, and Major M&A Pipeline in 2025 Annual Report
Summary
Vireo Growth Inc. reported a 170% revenue increase and achieved positive operating cash flow in 2025, driven by successful mergers and a strong pipeline of pending acquisitions. The company also settled a major litigation and noted potential federal tax relief from cannabis rescheduling.
Key Events
-
Strong 2025 Financial Performance
Total revenue increased by 170% to $268.8 million in 2025, up from $99.4 million in 2024. Adjusted EBITDA surged to $74.7 million in 2025 from $25.1 million in 2024.
-
Positive Operating Cash Flow Achieved
The company generated $3.7 million in cash from operating activities in 2025, a significant improvement from a $10.2 million cash burn in 2024.
-
Significant M&A Activity Completed
Vireo Growth Inc. successfully closed mergers with WholesomeCo, Inc., Proper Holdings Management, Inc., NGH Investments, Inc., and Deep Roots Holdings, Inc. in 2025, expanding operations into Utah, Nevada, and Missouri.
-
Major Pending Acquisitions Announced
As of December 31, 2025, the company had definitive agreements for the acquisition of Eaze Inc. (estimated $47.0M), Colorado dispensary assets from PharmaCann Inc. (estimated $49.0M), and assets from Schwazze (valued at $78.0M), all to be paid in subordinate voting shares.
Analysis
Vireo Growth Inc.'s 2025 annual report details a period of significant expansion and operational improvement, marked by substantial revenue growth and a shift to positive cash flow from operations. The company's strategic focus on M&A has driven a 170% increase in total revenue and a near-tripling of Adjusted EBITDA. The successful integration of three major mergers in 2025 (Wholesome, Proper, and Deep Roots) expanded its footprint into Utah, Nevada, and Missouri. Furthermore, the company has a robust pipeline of pending acquisitions, including Eaze Inc. (estimated $47.0M), Colorado dispensary assets from PharmaCann Inc. (estimated $49.0M), and assets from Schwazze (valued at $78.0M), signaling continued aggressive growth. The resolution of the Verano litigation, resulting in a $9.17 million settlement for Vireo, removes a significant legal overhang. While the company continues to report a net loss, the positive operating cash flow and strong Adjusted EBITDA growth indicate improving underlying business health and operational efficiency. The potential federal rescheduling of marijuana to Schedule III, as directed by a December 2025 executive order, could offer substantial federal tax relief, a critical development for cannabis companies. The non-binding MOU with Scotts Miracle-Gro for The Hawthorne Gardening Company also points to potential future strategic diversification into federally legal, non-plant touching segments of the cannabis industry.
At the time of this filing, VREOF was trading at $0.42 on OTC in the Life Sciences sector, with a market capitalization of approximately $455.4M. The 52-week trading range was $0.31 to $0.80. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.